Tachykinin receptors antagonism for asthma: a systematic review.

Tachykinin receptors antagonism for asthma: a systematic review.
复制标题

DOI:
10.1186/1471-2466-11-41
复制
发表时间:
2011-08-02
影响因子:
3.1
通讯作者:
Moreira A
Moreira A
中科院分区:
医学3区
文献类型:
--
作者:
Ramalho R;Soares R;Couto N;Moreira A

文献摘要

参考文献

被引文献

相似文献

速激肽P物质、神经激肽A和神经激肽B似乎通过介导神经源性炎症和肺力学的几个方面来解释哮喘的病理生理学。这些神经肽主要通过其受体NK 1、NK 2和NK 3发挥作用,可能成为新的哮喘治疗靶点。本文对速激肽受体拮抗剂治疗哮喘的随机对照试验进行了系统回顾。以症状、气道炎症、肺功能和气道炎症作为结局。我们检索了科克伦航空集团哮喘试验专业注册库、科克伦系统评价数据库、MEDLINE/PubMed和EMBASE。搜索截至2010年6月。纳入研究的质量评级遵循科克伦协作网和GRADE Profiler方法。然而,由于研究中的测量方法不同,数据未汇总。我们的系统评价显示NK受体拮抗剂有降低气道反应性和改善肺功能的潜力。然而,对气道炎症和哮喘症状的影响很差或没有描述。有限的证据表明速激肽受体拮抗剂可能降低哮喘患者的气道反应性,改善肺功能。还需要进一步的大型随机试验。
Tachykinins substance P, neurokinin A and neurokinin B seem to account for asthma pathophysiology by mediating neurogenic inflammation and several aspects of lung mechanics. These neuropeptides act mainly by their receptors NK1, NK2 and NK3, respectively which may be targets for new asthma therapy. This review systematically examines randomized controlled trials evaluating the effect of tachykinins receptors antagonism on asthma. Symptoms, airway inflammation, lung function and airway inflammation were considered as outcomes. We searched the Cochrane Airways Group Specialized Register of Asthma Trials, Cochrane Database of Systematic Reviews, MEDLINE/PubMed and EMBASE. The search is as current as June 2010. Quality rating of included studies followed the Cochrane Collaboration and GRADE Profiler approaches. However, data were not pooled together due to different measures among the studies. Our systematic review showed the potential of NK receptor antagonist to decrease airway responsiveness and to improve lung function. However, effects on airway inflammation and asthma symptoms were poorly or not described. The limited available evidence suggests that tachykinin receptors antagonists may decrease airway responsiveness and improve lung function in patients with asthma. Further large randomized trials are still required.
DOI: 10.1371/journal.pmed.1000097
发表时间: 2009-07-21
期刊: PLoS medicine
影响因子: 15.8
作者:
Moher D;Liberati A;Tetzlaff J;Altman DG;PRISMA Group
通讯作者: PRISMA Group
DOI: 10.1016/j.vph.2005.08.031
发表时间: 2006-10-01
影响因子: 4
作者:
Canning, Brendan J.
通讯作者: Canning, Brendan J.
DOI: 10.1164/ajrccm.159.2.9804125
发表时间: 1999-02-01
影响因子: 24.7
作者:
Schuiling, M;Zuidhof, AB;Meurs, H
通讯作者: Meurs, H
DOI: 10.1183/09031936.03.00101902
发表时间: 2004-01-01
影响因子: 24.3
作者:
Joos, GF;Vincken, W;Pauwels, RA
通讯作者: Pauwels, RA
DOI: 10.1183/09031936.98.12010017
发表时间: 1998-07-01
影响因子: 24.3
作者:
Van Schoor, J;Joos, GF;Pauwels, RA
通讯作者: Pauwels, RA